Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 13/20 | 0.50 |
| ▸ | THRB | P10828 | 13/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HNF4A | P41235 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13381672 | 0.90 | THRA (0.44) | THRATHRBSLC7A5OPRK1MEN1 | |
| SCHEMBL13382166 | 0.90 | THRA (0.49) | THRATHRBALOX15KMT2AHSD17B10 | |
| SCHEMBL27666494 | 0.84 | THRA (0.48) | THRATHRBSLC7A5OPRK1MEN1 | |
| SCHEMBL13381760 | 0.83 | THRA (0.47) | THRATHRBALOX15KMT2AHSD17B10 | |
| SCHEMBL4964413 | 0.83 | THRA (0.47) | THRATHRBSLC7A5OPRK1MEN1 | |
| SCHEMBL281929 | 0.82 | THRA (0.63) | THRATHRBSLC7A5OPRK1MEN1 | |
| SCHEMBL282342 | 0.81 | THRA (0.47) | THRATHRBSLC7A5OPRK1MEN1 | |
| Vk-0214 SCHEMBL283442 | 0.80 | THRB (0.79) | THRATHRBSLC7A5OPRK1MEN1 | |
| SCHEMBL12824842 | 0.79 | MEN1 (0.51) | THRATHRBSLC7A5OPRK1MEN1 | |
| SCHEMBL25856594 | 0.76 | THRB (0.67) | THRATHRBSLC7A5OPRK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11707472-B2 | Compositions for the treatment of fibrosis | VIKING THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11707472-B2 | Compositions for the treatment of fibrosis | VIKING THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230226038-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS | VIKING THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230226038-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS | VIKING THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20220016136-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS | VIKING THERAPEUTICS, INC. | 2022-01-20 | — | — | US | disclosed |
| US-20220016137-A1 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND INFLAMMATION | VIKING THERAPEUTICS, INC. | 2022-01-20 | — | — | US | disclosed |
| US-11202789-B2 | Method of treating glycogen storage disease | VIKING THERAPEUTICS, INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-10925885-B2 | Thyromimetics for the treatment of fatty liver diseases | METABASIS THERAPEUTICS, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| WO-2020117987-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS | VIKING THERAPEUTICS, INC. (US) | 2020-06-11 | — | — | WO | disclosed |
| US-20200179412-A1 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS | VIKING THERAPEUTICS, INC. | 2020-06-11 | — | — | US | disclosed |
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | METABASIS THERAPEUTICS, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | METABASIS THERAPEUTICS, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | METABASIS THERAPEUTICS, INC. | 2009-01-29 | — | — | US | disclosed |
| EP-1891080-A2 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | Metabasis Therapeutics, Inc. (US) | 2008-02-27 | — | — | EP | disclosed |
| EP-1890768-A2 | NOVEL PHOSPHINIC ACID-CONTAINING THYROMIMETICS | Metabasis Therapeutics, Inc. (US) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006128056-A2 | NOVEL PHOSPHINIC ACID-CONTAINING THYROMIMETICS | METABASIS THERAPEUTICS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006128055-A2 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | METABASIS THERAPEUTICS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| EP-1689383-A2 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | Metabasis Therapeutics, Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20060046980-A1 | Novel phosphorus-containing thyromimetics | METABASIS THERAPEUTICS, INC. | 2006-03-02 | — | — | US | disclosed |
| WO-2005051298-A2 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | METABASIS THERAPEUTICS, INC. (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220016136-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS | FABP1, SLC10A1, TSHR | THRA 8/4885THRB 7/4885SLC7A5 1325/4885 |
| US-10925885-B2 | Thyromimetics for the treatment of fatty liver diseases | TSHR, THRA, FABP1 | THRA 2/4885THRB 4/4885SLC7A5 648/4885 |
| US-20220016137-A1 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND INFLAMMATION | COL2A1, COL1A1, TGFBR2 | THRA 187/4885THRB 30/4885SLC7A5 4830/4885 |
| US-11707472-B2 | Compositions for the treatment of fibrosis | COL2A1, TGFBR2, COL1A1 | THRA 251/4885THRB 33/4885SLC7A5 4786/4885 |
| US-20200179412-A1 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS | COL2A1, TGFBR2, COL1A1 | THRA 251/4885THRB 33/4885SLC7A5 4786/4885 |
| US-20060046980-A1 | Novel phosphorus-containing thyromimetics | PYGL, THRA, THOP1 | THRA 2/4885THRB 6/4885SLC7A5 740/4885 |
| US-11202789-B2 | Method of treating glycogen storage disease | GYS2, GYS1, PYGL | THRA 9/4885THRB 7/4885SLC7A5 2346/4885 |
| US-20230226038-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS | FABP1, SLC10A1, LIPC | THRA 25/4885THRB 19/4885SLC7A5 2475/4885 |
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | PYGL, PHOSPHO1, LIPE | THRA 14/4885THRB 41/4885SLC7A5 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.